Sage Journals: Discover world-class research

Abstract

Our goal was to determine if paraoxonase 1 (PON1) activity relates to the presence of metabolic syndrome (MS) and inflammation in HIV patients treated with highly active antiretroviral therapy (HAART). This was a prospective, multicenter study including 269 patients receiving HAART for at least 1 year and a maximum of 4 years. PON1 and inflammatory markers [C reactive protein (CRP), interleukin-6 (IL-6), serum amyloid A (SAA), and soluble tumor necrosis factor receptors 2 (sTNF-R2)] were compared between patients with or without MS and the association between inflammatory markers and PON1 was assessed by logistic regression analyses. MS was found in 18.2% of the patients. Inflammatory markers, with the exception of sTNF-R2, were significantly higher, while PON1 activity was significantly lower in the presence of metabolic syndrome. PON1 activity was significantly related to apolipoprotein C3, CD4 count, and sTNF-R2. It may be concluded that PON1 appears to be a marker for the metabolic syndrome in HIV-infected subjects. PON1 activity is related to dyslipidemia and the immunological status of the patients but is not fully determined by inflammation.

Get full access to this article

View all access options for this article.

References

Bard

, Lassalle

, Capeau

et al. Association of apolipoproteins C3 and E with metabolic changes in HIV-infected adults treated with a protease-inhibitor-containing antiretroviral therapy. Antivir Ther, 2006; 11:361–370.

Biron

, Bobin-Dubigeon

, Volteau

et al. Metabolic syndrome in French HIV-infected patients: Prevalence and predictive factors after 3 years of antiretroviral therapy. AIDS Res Hum Retroviruses, 2012; 28:1672–1678.

Mackness

, Arrol

, Durrington

. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett, 1991; 286:152–154.

Parra

, Alonso-Villaverde

, Coll

et al. Serum paraoxonase-1 activity and concentration are influenced by human immunodeficiency virus infection. Atherosclerosis, 2007; 194:175–181.

Banka

, Yuan

, de Beer

et al. Serum amyloid A (SAA): Influence on HDL-mediated cellular cholesterol efflux. J Lipid Res, 1995; 36:1058–1065.

Grundy

, Brewer HB

, Cleeman

et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation, 2004; 109:433–438.

Jerico

, Knobel

, Montero

et al. Metabolic syndrome among HIV-infected patients: Prevalence, characteristics, and related factors. Diabetes Care, 2005; 28:132–137.

Samaras

, Wand

, Law

et al. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: Associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Diabetes Care, 2007; 30:113–119.

Lemieux

, Pascot

, Prud'homme

et al. Elevated C-reactive protein: Another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol, 2001; 21:961–967.

10.

Fasshauer

, Kralisch

, Klier

et al. Interleukin-6 is a positive regulator of tumor necrosis factor alpha-induced adipose-related protein in 3T3-L1 adipocytes. FEBS Lett, 2004; 560:153–157.

11.

Luc

, Bard

, Juhan-Vague

et al. C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: The PRIME Study. Arterioscler Thromb Vasc Biol, 2003; 23:1255–1261.

12.

Kraja

, Province

, Arnett

et al.

Do inflammation and procoagulation biomarkers contribute to the metabolic syndrome cluster?

Nutr Metab (Lond), 2007; 4:28.

13.

Browning

, Krebs

, Magee

et al. Circulating markers of inflammation and their link to indices of adiposity. Obes Facts, 2008; 1:259–265.

14.

Aderka

. The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev, 1996; 7:231–240.

15.

Dzienis-Straczkowska

, Straczkowski

, Szelachowska

et al. Soluble tumor necrosis factor-alpha receptors in young obese subjects with normal and impaired glucose tolerance. Diabetes Care, 2003; 26:875–880.

16.

Liu

, Young

, Zinman

et al. Lifestyle variables, non-traditional cardiovascular risk factors, and the metabolic syndrome in an Aboriginal Canadian population. Obesity (Silver Spring), 2006; 14:500–508.

17.

Parra

, Coll

, Aragones

et al. Nonconcordance between subclinical atherosclerosis and the calculated Framingham risk score in HIV-infected patients: Relationships with serum markers of oxidation and inflammation. HIV Med, 2010; 11:225–231.

18.

Van Lenten

, Hama

, de Beer

et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest, 1995; 96:2758–2767.

19.

Parra

, Marsillach

, Aragones

et al. Paraoxonase-1 gene haplotypes are associated with metabolic disturbances, atherosclerosis, and immunologic outcome in HIV-infected patients. J Infect Dis, 2010; 201:627–634.

Short Communication: Paraoxonase 1 (PON1) in French HIV-Infected Patients Under Antiretroviral Therapy: Relationship with the Metabolic Syndrome and Inflammation

Abstract

Get full access to this article

References